biostudies-literatureUnknown27(7)Ashizawa N<h4>Introduction</h4>Numerous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests exists commercially; however, their performance using clinical samples is limited. Although insufficient to detect SARS-CoV-2 in the early phase of infection, antibody assays can be of great use for surveillance studies or for some coronavirus disease 2019 (COVID-19) patients presenting late to the hospital.<h4>Methods</h4>This study evaluated the sensitivity and specificity of four commercial SARS-CoV-2 lateral flow antibody tests using 213 serum specimens from 90 PCR-positive confirmed COVID-19 patients. Of 59 negative control sera, 50 were obtained from patients with other respiratory infectious diseases before COVID-19 pandemic began while nine were from patients infected with other respiratory viruses, including two seasonal coronaviruses.<h4>Results</h4>The varied sensitivities for the four commercial kits were 70.9%, 65.3%, 45.1%, and 65.7% for BioMedomics, Autobio Diagnostics, Genbody, and KURABO, respectively, between sick days 1 and 155 in COVID-19 patients. The sensitivities of the four tests gradually increased over time after infection before sick day 5 (15.0%, 12.5%, 15.0%, and 20.0%); from sick day 11-15 (95.7%, 87.2%, 53.2%, and 89.4%); and after sick day 20 (100%, 100%, 68.6%, and 96.1%), respectively. For severe illness, the sensitivities were quite high in the late phase after sick day 15. The specificities were over 96% for all four tests. No cross-reaction due to other pathogens, including seasonal coronaviruses, was observed.<h4>Conclusions</h4>Our results demonstrated the large differences in the antibody test performances. This ought to be considered when performing surveillance analysis.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy1033-1038https://www.ebi.ac.uk/biostudies/studies/S-EPMC7959261biostudies-literatureEvaluation of four commercial severe acute respiratory coronavirus 2 antibody tests.PMC7959261Hirayama TSawai TYamamoto KYanagihara KOkamoto MFukushima KYatera KOhyama KYamanashi HImamura YTakazono TFukuda YHosogaya NMiyazaki TTanaka TMukae HNagasaki YTashiro MKawanami TIzumikawa KAshizawa NTakahashi KfalseEvaluation of four commercial severe acute respiratory coronavirus 2 antibody tests.<h4>Introduction</h4>Numerous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests exists commercially; however, their performance using clinical samples is limited. Although insufficient to detect SARS-CoV-2 in the early phase of infection, antibody assays can be of great use for surveillance studies or for some coronavirus disease 2019 (COVID-19) patients presenting late to the hospital.<h4>Methods</h4>This study evaluated the sensitivity and specificity of four commercial SARS-CoV-2 lateral flow antibody tests using 213 serum specimens from 90 PCR-positive confirmed COVID-19 patients. Of 59 negative control sera, 50 were obtained from patients with other respiratory infectious diseases before COVID-19 pandemic began while nine were from patients infected with other respiratory viruses, including two seasonal coronaviruses.<h4>Results</h4>The varied sensitivities for the four commercial kits were 70.9%, 65.3%, 45.1%, and 65.7% for BioMedomics, Autobio Diagnostics, Genbody, and KURABO, respectively, between sick days 1 and 155 in COVID-19 patients. The sensitivities of the four tests gradually increased over time after infection before sick day 5 (15.0%, 12.5%, 15.0%, and 20.0%); from sick day 11-15 (95.7%, 87.2%, 53.2%, and 89.4%); and after sick day 20 (100%, 100%, 68.6%, and 96.1%), respectively. For severe illness, the sensitivities were quite high in the late phase after sick day 15. The specificities were over 96% for all four tests. No cross-reaction due to other pathogens, including seasonal coronaviruses, was observed.<h4>Conclusions</h4>Our results demonstrated the large differences in the antibody test performances. This ought to be considered when performing surveillance analysis.2021-01-01T00:00:00Z2021 Jul2024-11-09T22:21:39.522Z2022-02-10T12:56:15.255ZS-EPMC79592613378169110.1016/j.jiac.2021.03.008